Upside in Lucid (LCID) attributed to report President Trump bought shares in the co. - unconfirmed
Newsquawk Staff ·
Upside in Lucid (LCID) attributed to report President Trump bought shares in the co. - unconfirmed.
What it means
Single-name moves attributed to an unconfirmed report of a political figure's personal share purchase sit in the rumour bucket, and the established pattern with such headlines is a sharp, thin-liquidity pop that fades if no filing or confirmation follows. The verification channel here is concrete: any insider or affiliate accumulation by a senior officeholder would ultimately surface through disclosure requirements, and the absence of such a filing is what has historically unwound comparable episodes. The distinction worth drawing is between genuine positioning and symbolic association, since names linked to a political brand have on previous occasions traded as proxies for perceived favour rather than fundamentals, with the premium proving durable only where a policy or commercial tie-in subsequently materialised. For an EV name already trading on sentiment and capital-raise overhangs, the float dynamics tend to amplify the initial spike relative to the information content. The follow-ons are any confirmation or denial, whether the move attracts volume beyond the headline algo flow, and whether peers in the space trade in sympathy or the move stays idiosyncratic. Until sourcing firms up, the headline carries rumour status and the price action should be read accordingly.
- Instacart (CART) is reportedly exploring a sale, The Information reports; held talks with DoorDash (DASH) and Uber (UBER)
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED
Related headlines
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans2 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL3 hours ago
- Moonshot AI unveils 2.8tln-parameter Kimi K3.1 Pro model; says it beats Opus 5.5 and GPT-6 Astra on long-horizon coding tasks and scores top marks on SWE Marathon and agent benchmarks; pledges open weights for the 3tln-class model by November 4th3 hours ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS4 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20275 hours ago
- OpenAI reveals plans for an in-house exabyte-scale storage system5 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter5 hours ago
- Upside in Penguin Solutions (PEGN) attributed to M&A chatter - UNCONFIRMED 5 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability5 hours ago
- US President Trump says Elon Musk will not do anything wrong regarding access to Starlink (SPCX) in Ukraine6 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)6 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed6 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce7 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders7 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer7 hours ago